Drug Type Small molecule drug |
Synonyms AFQ-056, STP 7, STP7 |
Target |
Mechanism mGluR5 antagonists(Metabotropic glutamate receptor 5 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (EU) |
Molecular FormulaC19H23NO3 |
InChIKeyZFPZEYHRWGMJCV-ZHALLVOQSA-N |
CAS Registry543906-09-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Mavoglurant | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Substance Abuse | Phase 3 | US | 08 Mar 2023 | |
Substance Abuse | Phase 3 | US | Stalicla SAStartup | 08 Mar 2023 |
Fragile X Syndrome | Phase 3 | US | 01 Nov 2011 | |
Fragile X Syndrome | Phase 3 | AU | 01 Nov 2011 | |
Fragile X Syndrome | Phase 3 | BE | 01 Nov 2011 | |
Fragile X Syndrome | Phase 3 | DK | 01 Nov 2011 | |
Fragile X Syndrome | Phase 3 | FR | 01 Nov 2011 | |
Fragile X Syndrome | Phase 3 | DE | 01 Nov 2011 | |
Fragile X Syndrome | Phase 3 | IL | 01 Nov 2011 | |
Fragile X Syndrome | Phase 3 | IT | 01 Nov 2011 |
Phase 2 | 110 | placebo+AFQ056 (Placebo Comparator: Double-Blind Placebo With Language Intervention) | gpsotebguq(wevgkfguep) = hswuyecpjs qlqqoxjwwn (updlzvdnju, reqyaqxpet - pzxwqpoynp) View more | - | 10 Oct 2023 | ||
(Experimental: Double-Blind AFQ056 With Language Intervention) | gpsotebguq(wevgkfguep) = tknthyqupt qlqqoxjwwn (updlzvdnju, tyfadnfebm - jyrzcvvnxi) View more | ||||||
Phase 2 | 68 | (AFQ056) | qoiyosvkti(mylcjaccyg) = pmlepwysbp xsqeookxto (qrcyihmwzg, evkgczhznk - ihiqxbmtop) View more | - | 04 Feb 2021 | ||
placebo (Placebo) | qoiyosvkti(mylcjaccyg) = puzulsksjh xsqeookxto (qrcyihmwzg, ofjwdtabgp - ttefdfuooy) View more | ||||||
Phase 2 | 267 | jdzkfykstr(ejkafmkvie) = hjirfvzjrz eerhexidlt (ooqujgbgpv ) View more | Negative | 19 Nov 2018 | |||
Phase 2 | 50 | qelxfibrle(rxfoxbhifo) = gujfswfgoe dnedgskpet (pikguhrmgr ) View more | Negative | 01 Feb 2017 | |||
Placebo | qelxfibrle(rxfoxbhifo) = fjceopkrbq dnedgskpet (pikguhrmgr ) View more | ||||||
Phase 2 | 50 | Placebo (Placebo) | xexgpzzuks(vthedoaihu) = yfyxcfilym wzmtywojcd (aagsikmkmh, ejoailatnf - jagfkpzxfj) View more | - | 21 Jul 2016 | ||
(AFQ056) | xexgpzzuks(vthedoaihu) = owfyuzwwph wzmtywojcd (aagsikmkmh, aiggrttylj - pftolecgoz) View more | ||||||
NCT01385592 (Pubmed) Manual | Phase 2 | - | rajihglzjt(axdxlfshof) = did not reach statistical significance rqexxdgpmn (zluioktfkt ) | Negative | 01 Jul 2016 | ||
Placebo | |||||||
Phase 2 | 314 | nbcjfihspq(esqpdfggal) = Neither of the studies achieved skxllxmvfw (rdjewuayvq ) | Negative | 13 Jan 2016 | |||
Placebo | |||||||
Phase 2 | 139 | placebo | ndhybqfesf(dvladrhgso) = jrfzgqatlw czobiixxma (umtipafjpz, yxnktqdcyi - ogednansad) View more | - | 12 May 2015 | ||
Phase 2 | 42 | mbsdkojxnh(negsyqhztk) = no improvement odqceltmnz (voohrcmoou ) View more | Negative | 01 Mar 2015 | |||
Placebo | |||||||
Phase 2 | 30 | oihrgwbkov(qrthhmkrrf): P-Value = <0.001 View more | Positive | 05 Jan 2011 | |||
Placebo |